Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05710315 · ClinicalTrials.gov registry record · NA
Evaluating the Utility of RELiZORB™ for Treating Feeding Intolerance in Critically Ill Adults With Multi-Organ Failure
A NA study of Exocrine Pancreatic Insufficiency and Multi Organ Failure, sponsored by Inova Health Care Services.
- Recruiting
- Registry status
- NA
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT05710315 is a NA study of Exocrine Pancreatic Insufficiency and Multi Organ Failure that is actively recruiting participants, run by Inova Health Care Services. The registered enrollment target is 32 participants, below the 1,221-participant average among 7 other Exocrine Pancreatic Insufficiency trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05710315, a NA study of Exocrine Pancreatic Insufficiency and Multi Organ Failure, is actively recruiting participants, sponsored by Inova Health Care Services.
- RECRUITING
- Registry status
- NA
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to determine if the use of RELiZORB™ improves nutrition tolerance and helps critically ill patients meet their nutrition goals. RELiZORB™ is a digestive enzyme cartridge that contains lipase and works as a pancreatic enzyme replacement. It promotes breaking down fat and helps the body absorb it. The device connects with tube feedings to help the body with digestion. RELiZORB™ is approved by the U.S. Food and Drug Administration (FDA) for use with tube feedings in patients 5 years of age or older. While the use of RELiZORB™ in this study is consistent with the FDA approval, the use of RELiZORB™ in patients with multi organ failure is not in the current standard of care practice at Inova Health Care facilities.
Conditions Studied
Interventions
- OTHER Placebo
- DEVICE RELiZORB™
Study Locations (1)
Virginia
- Inova Fairfax Medical Campus - Falls Church
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2025-05-07 |
| Est. Completion | 2026-05-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05710315
The ClinicalTrials.gov registry entry for NCT05710315 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,221-participant average among 7 other Exocrine Pancreatic Insufficiency trials with a reported enrollment target (97% lower). The listed sponsor is Inova Health Care Services, which has 75 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Exocrine Pancreatic Insufficiency appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05710315 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT05710315 about?
NCT05710315 is a clinical study titled "Evaluating the Utility of RELiZORB™ for Treating Feeding Intolerance in Critically Ill Adults With Multi-Organ Failure". The purpose of this research is to determine if the use of RELiZORB™ improves nutrition tolerance and helps critically ill patients meet their nutrition goals. RELiZORB™ is a digestive enzyme cartridge that contains lipase and works as a pancreatic enzyme replacement. It promotes breaking down fat a...
What is the current status of trial NCT05710315?
This trial is currently recruiting. It is a NA study. The enrollment target is 32 participants. The study started on 2025-05-07. Estimated completion is 2026-05-31.
What conditions does trial NCT05710315 study?
This clinical trial studies the following conditions: Exocrine Pancreatic Insufficiency, Multi Organ Failure.
What interventions are being tested in trial NCT05710315?
The interventions under investigation include: Placebo (OTHER), RELiZORB™ (DEVICE).
Who is sponsoring clinical trial NCT05710315?
This trial is sponsored by Inova Health Care Services, which has 75 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05710315 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Exocrine Pancreatic Insufficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Shwachman-Diamond Syndrome Global Patient Survey and Partnering Platform
RECRUITING
-
THE Malabsorption Blood Test Trial Will Help Determine THE Benefits OF Pancreatic Enzyme Replacement Therapy IN Patients With Mild TO Moderate Exocrine Pancreatic Insufficiency.
RECRUITING · Phase 4
-
Pancreatic Enzyme Replacement Therapy for Acute Pancreatitis-Associated Exocrine Pancreatic Insufficiency
RECRUITING · Phase 4
-
PR-018: An Open-Label, Safety Extension of Study PR-011
COMPLETED · Phase 4
-
Open-Label Phase III Long-Term Safety Trial of Liprotamase
COMPLETED · Phase 3
-
SIMPLICITY: Studying Impacts on Malabsorption With Liprotamase in Cystic Fibrosis
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.